Dima Sobko / Shutterstock.com
A US court has brought to a close a patent lawsuit that cancer care company Helsinn Healthcare filed against Teva after determining that Helsinn did not trigger the on-sale bar provision when marketing its anti-cancer drug Aloxi (palonosetron).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Helsinn Healthcare, Teva, America Invents Act, patent infringement, Aloxi, palonosetron, on-sale patent bar